Showing results (151-160 of 242) with videos related to

Sort By:
Pageof 25
The Oncologist|July 3, 2024
Cisplatin eligibility in the neoadjuvant setting of patients with muscle-invasive bladder cancer undergoing radical cystectomyRenate Pichler, Josef Fritz, Andrea Mari, et al.
Annals of the Rheumatic Diseases|March 18, 2026
Risk score for early mortality to stratify for intensive SSc therapy in the EUSTAR network: the RESIST scoreAnn-Christin Pecher, Marouane Boubaya, Yannick Allanore, et al.
European Urology Oncology|May 14, 2025
Patient-reported Outcomes in KEYNOTE-921: Pembrolizumab with Docetaxel and Prednisone for Patients with Metastatic Castration-resistant Prostate CancerNobuaki Matsubara, Daniel Petrylak, Raffaele Ratta, et al.
European Urology|July 31, 2014
The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic reviewHarman M Bruins, Erik Veskimae, Virginia Hernandez, et al.
European Journal of Cancer (Oxford, England : 1990)|January 23, 2025
Reduced monocytic IL10 expression in PD1 inhibitor-treated patients is a harbinger of severe immune-related adverse eventsStanislav Rosnev, Baldur Sterner, Phillip Schiele, et al.
European Urology Open Science|November 13, 2023
Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial CarcinomaEnrique Grande, Aristotelis Bamias, Matthew D Galsky, et al.
JNCI Cancer Spectrum|April 16, 2024
Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrationsAndrea Necchi, Rodryg Ramlau, Alejandro Falcón González, et al.
Journal of Autoimmunity|July 28, 2020
Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patientsLorenzo M Canziani, Serena Trovati, Enrico Brunetta, et al.
European Urology|May 9, 2015
SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell CancerChristian Eichelberg, Walter L Vervenne, Maria De Santis, et al.
Rheumatology (Oxford, England)|November 26, 2019
Cardiac magnetic resonance predicts ventricular arrhythmias in scleroderma: the Scleroderma Arrhythmia Clinical Utility Study (SAnCtUS)Sophie Mavrogeni, Luna Gargani, Alessia Pepe, et al.
Pageof 25